罗氟司特治疗支气管哮喘急性加重对INF-γ及FVC指标的改善效果

杰希 科斯
布瑞科兴医药科技

摘要

目的：分析支气管哮喘急性加重患者采取罗氟司特治疗的效果。方法：本研究对象为2020年1月-2021年1月的64例支气管哮喘急性加重期患者。按照随机数字表法分为实验组（32例，罗氟司特治疗），对照组（32例，布地奈德悬浊液治疗），比较分析两组治疗效果。结果：实验组肺功能指标相比较对照组较高（P＜0.05）。实验组炎性因子指标中，INF-γ相比较对照组较高（P＜0.05），TNF-α、IL-17相比较对照组较低（P＜0.05）。实验组不良反应发生率与对照组比较差异较小，无统计学含义（P＞0.05）。结论：在支气管哮喘急性加重患者采取罗氟司特治疗的效果较为凸显，能够改善其肺功能指标以及炎性因子指标，且具有较好的治疗安全性。可见此种治疗方法能够在临床上推广应用。

关键词

罗氟司特；布地奈德悬浊液；肺功能指标；炎性因子指标；不良反应

参考

[1] Yanan Zhang. Effect of roflumilast combined with inhaled budesonide suspension on pulmonary function and serum levels of inflammatory factors in patients with acute exacerbation of bronchial asthma [J]. Clinical Medicine, 2022,42 (02): 93-95.

[2] Jianbo Lei, Zhengping He, Chunbao Xie. Roflumilast treatment for acute exacerbation of bronchial asthma and its effects on pulmonary function and serological indicators [J]. Journal of Practical Hospital, 2021,18 (01): 56-59.

[3] Chuntian Chi, Jian Zhou, Mingchun Zhang. Effect of budesonide formoterol combined with montelukast sodium on serum eotaxin-2 and IL-33 levels in patients with the acute onset of bronchial asthma [J]. Practical Medicine and Clinical, 2021,24 (12): 1087-1089.

[4] Qingliang Wu. Effect of adjuvant montelukast sodium therapy in the acute episode of bronchial asthma [J]. Fujian Medical Journal, 2021,43 (03): 94-95.

[5] Wei Qian, Hao Xiong. Effect of roflumilast on inflammation and oxidative stress response in patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Air Force Journal of Medicine, 2021,37 (01): 63-66.

[6] Runnan Chen, Lei Zhu. Progress in the treatment of roflumstrast in bronchial asthma [J]. Chinese Journal of Tuberculosis and Breath, 2020,43 (08): 698-701.